Children with X-linked hypophosphatemia, a rare genetic disorder affecting phosphate metabolism, have high rates of high blood pressure (17%) and heart muscle thickening (22%), with obesity being the primary factor driving these complications. According to Gram Research analysis of 252 children, obesity was associated with an 8.2-point increase in systolic blood pressure and significantly higher risk of heart muscle thickening.
A new study of 252 children with X-linked hypophosphatemia (XLH), a rare genetic disorder affecting how the body handles phosphate, found that 17% developed high blood pressure and 22% showed signs of heart strain. Gram Research analysis reveals that obesity was the strongest factor connected to these heart problems. The research combined data from clinical trials and hospital records to understand how this genetic condition affects children’s cardiovascular health. Doctors are now investigating whether a newer treatment called burosumab might help prevent these complications better than traditional phosphate supplements.
Key Statistics
A 2026 study of 252 children with X-linked hypophosphatemia found that 17% had high blood pressure and 22% showed signs of heart muscle thickening, with obesity present in 51% of the cohort at baseline.
Research published in the Journal of Bone and Mineral Research showed that obesity in children with X-linked hypophosphatemia was associated with an 8.2-point increase in systolic blood pressure compared to non-obese children.
Among 50 children with X-linked hypophosphatemia who underwent heart ultrasounds, 22% (11 children) already showed signs of left ventricular hypertrophy, a thickening of the heart muscle that can impair heart function.
A multivariable analysis of 1,555 blood pressure readings from 252 children with X-linked hypophosphatemia identified obesity as the main factor associated with both increased blood pressure and heart muscle thickening.
The Quick Take
- What they studied: Whether children with a rare genetic condition called X-linked hypophosphatemia develop high blood pressure and heart problems, and what factors contribute to these complications.
- Who participated: 252 children with X-linked hypophosphatemia from four different medical centers and research programs. About half of the children were overweight or obese at the start of the study.
- Key finding: Seventeen percent of children with this genetic condition had high blood pressure, and 22% showed signs that their heart muscle had thickened abnormally. Obesity was the main factor linked to both problems.
- What it means for you: If your child has X-linked hypophosphatemia, monitoring weight and blood pressure becomes especially important for heart health. Talk with your doctor about weight management strategies and regular heart checkups. This research suggests that controlling obesity may help prevent serious heart complications in children with this condition.
The Research Details
Researchers combined information from multiple sources to get a complete picture of heart health in children with X-linked hypophosphatemia. They used data from a major clinical trial comparing two different treatments (burosumab versus traditional phosphate and vitamin D supplements), a disease monitoring program that tracks patients over time, and medical records from two major hospitals. This approach gave them 1,555 blood pressure measurements from 252 children, plus heart ultrasound images from 50 of those children. The researchers defined high blood pressure using age-appropriate standards, since normal blood pressure ranges change as children grow. They used statistical methods designed for analyzing data collected multiple times from the same people over time.
By combining data from different sources, researchers could study a larger group of children than any single hospital could provide. This is important because X-linked hypophosphatemia is rare, so finding enough patients to study requires looking across multiple medical centers. The study also compared two different treatment approaches, which helps doctors understand whether newer medications might offer advantages for heart health beyond traditional treatments.
This study has several strengths: it included a randomized controlled trial component (considered the gold standard for medical research), combined prospective data (collected going forward) with retrospective data (looking back at medical records), and used appropriate statistical methods for repeated measurements. However, the heart ultrasound data came from only 50 children, which is smaller than the full group. The study was published in a peer-reviewed journal focused on bone and mineral research, indicating it met scientific standards for publication.
What the Results Show
Among 252 children with X-linked hypophosphatemia, researchers found that 42 children (17%) had high blood pressure based on multiple blood pressure readings taken at different clinic visits. This rate is higher than expected in healthy children. Additionally, 51% of the children were overweight or obese at the start of the study, which is notably high. When researchers looked at heart ultrasounds from 50 children, they discovered that 11 children (22%) already had thickening of the heart muscle, a condition called left ventricular hypertrophy. This thickening is concerning because it can affect how well the heart pumps blood. The most important finding was that obesity was strongly linked to both high blood pressure and heart muscle thickening. Children who were overweight or obese had significantly higher blood pressure readings and were more likely to show signs of heart strain.
The study also examined whether the newer treatment burosumab had any effect on blood pressure compared to traditional phosphate and vitamin D supplements. Burosumab showed a small decrease in systolic blood pressure (the top number), but the researchers noted that longer follow-up studies are needed to determine if this translates to meaningful improvements in heart health over time. The research highlights that X-linked hypophosphatemia affects multiple body systems, and heart complications may be an underrecognized problem in this population.
Previous research has shown that people with X-linked hypophosphatemia have higher rates of obesity and cardiovascular problems compared to the general population. This study confirms those findings and provides specific numbers for children. The strong connection between obesity and heart problems in this group aligns with what doctors know about obesity in the general population, suggesting that weight management is universally important for heart health. However, this is one of the first studies to systematically examine heart muscle thickening in children with this specific genetic condition.
The study has several important limitations to consider. The heart ultrasound data came from only 50 children, so conclusions about heart problems may not apply to all children with this condition. The study combined data collected in different ways and at different times, which can introduce inconsistencies. The researchers could not determine whether the heart problems were caused directly by the genetic condition itself or primarily by obesity and high blood pressure. Additionally, the study was relatively short-term, so it cannot show whether these heart changes lead to serious problems later in life. Finally, because this is a rare condition, the results may not apply to other populations.
The Bottom Line
Children with X-linked hypophosphatemia should have regular blood pressure monitoring and weight management as part of their routine care. Heart ultrasounds may be appropriate for children in this group, especially those who are overweight or have high blood pressure. Families should work with their medical team to develop healthy eating and activity plans tailored to their child’s needs. These recommendations are based on solid evidence (the study directly measured these associations) but should be discussed with your child’s doctor, as individual circumstances vary.
This research is most relevant for families with children who have X-linked hypophosphatemia, their doctors, and genetic specialists. It’s also important for cardiologists (heart doctors) who may see patients with this condition. Parents of children with this genetic disorder should discuss these findings with their medical team. The general public should understand that rare genetic conditions can have unexpected effects on heart health, and that obesity is a risk factor even in children with genetic disorders.
Changes in blood pressure and weight can be measured within weeks to months. However, improvements in heart muscle thickening typically take longer to develop and may require 6 to 12 months or more of consistent weight management and blood pressure control. Heart health benefits from weight loss and blood pressure management are usually gradual, so patience and consistency are important.
Frequently Asked Questions
What is X-linked hypophosphatemia and why does it cause heart problems?
X-linked hypophosphatemia is a rare genetic disorder where the body cannot properly regulate phosphate levels, affecting bone development and multiple organ systems. This study found that children with this condition have higher rates of obesity and high blood pressure, which damage the heart muscle over time.
How common is high blood pressure in children with X-linked hypophosphatemia?
This research found that 17% of 252 children with X-linked hypophosphatemia had high blood pressure, which is significantly higher than the rate in healthy children. Obesity was the strongest predictor of who developed high blood pressure.
Can heart problems from X-linked hypophosphatemia be prevented?
This study suggests that managing obesity and blood pressure may help prevent heart complications in children with this condition. Weight management through diet and exercise appears to be the most important modifiable factor, though longer-term studies are needed to confirm this.
Is burosumab better than traditional treatment for protecting the heart?
The study found that burosumab showed a small decrease in blood pressure compared to traditional phosphate and vitamin D supplements, but researchers noted that longer follow-up is needed to determine if this translates to better heart outcomes over time.
Should children with X-linked hypophosphatemia have heart ultrasounds?
This research found that 22% of children with this condition showed signs of heart muscle thickening on ultrasound. Your child’s doctor may recommend heart ultrasounds, especially if your child is overweight or has high blood pressure.
Want to Apply This Research?
- Track your child’s blood pressure at home using a pediatric-appropriate blood pressure monitor, recording readings at the same time each day. Also track weight weekly and note any changes in activity level or diet. This data helps your doctor see patterns and adjust treatment if needed.
- Work with your child to increase daily physical activity to 60 minutes most days of the week through activities they enjoy (sports, dancing, biking, playing). Simultaneously, reduce sugary drinks and processed foods while increasing fruits, vegetables, and whole grains. Start with small, achievable changes rather than overhauling everything at once.
- Set monthly reminders to review blood pressure trends and weight changes with your child’s doctor. Use the app to flag any readings that are consistently high or show a concerning pattern. Schedule heart ultrasounds as recommended by your medical team, typically annually or as symptoms warrant.
This research describes medical findings in children with X-linked hypophosphatemia and should not be used for self-diagnosis or to replace professional medical advice. If your child has been diagnosed with X-linked hypophosphatemia or you suspect your child may have this condition, consult with a qualified physician or genetic specialist. Blood pressure monitoring, heart imaging, and treatment decisions should only be made under the guidance of your child’s healthcare provider. This article summarizes research findings and does not constitute medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.